 [25] 
  At the pre-trial stage, Sanofi, supported by Schering, brought a motion to bifurcate the proceeding. Apotex successfully resisted this motion. It is almost certain that, if Apotex had not resisted, the motion for bifurcation would have succeeded. To what extent, if any, should Apotex be "punished" for its resistance of the motion? 
